Soligenix increases at-market offering by $2.96M, total now up to $6.4M

SOLIGENIX, INC.

Filed prospectus supplement on May 28, 2026, increasing shares issuable under Sales Agreement with Rodman & Renshaw by $2,956,000.
Prior sales under the agreement totaled approximately $3,445,000; combined maximum now $6,401,000.
Common stock (SNGX) offered on Nasdaq; legal opinion from Duane Morris LLP filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.